| Publisher: American Medical Association
| ||||||||||||||||||||||||||||||
|
JAMA Oncology
Journal Prestige (SJR): 6.187  Citation Impact (citeScore): 6 Number of Followers: 44  Hybrid journal (It can contain Open Access articles)ISSN (Print) 2374-2437 - ISSN (Online) 2374-2445 Published by American Medical Association  [14 journals]
|
- JAMA Oncology
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1183 - 1183
Abstract: JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2022.4872
Issue No: Vol. 9, No. 9 (2023)
-
- Patients With Brain Metastases Deserve Better
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1197 - 1198
Abstract: This Viewpoint advocates for better research in treatments and clinical practice for brain metastasis stemming from lung cancer.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2129
Issue No: Vol. 9, No. 9 (2023)
-
- Short Bouts of Physical Activity for Good Health
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1199 - 1201
Abstract: The importance of lifestyle factors such as physical activity to decrease risk of common diseases is becoming increasingly clear from a growing number of studies and meta-analyses, although challenges in the interpretation of interstudy differences remain. The risk reduction for development of common noncommunicable diseases associated with being physically inactive has been shown to be substantial. A recent overview from the World Health Organization suggested that individuals who meet recommended levels of physical activity have a 20% to 30% reduced risk of premature death.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.1810
Issue No: Vol. 9, No. 9 (2023)
-
- Discarded Targeted Oral Anticancer Medication
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1202 - 1204
Abstract: Oral targeted agents for cancer are among the most expensive outpatient prescription drugs dispensed in the US. These drugs, often distributed as specialty drugs, can cost more than $170 000 per patient per year. Patients in the US pay a greater share of their health care costs than patients living in other developed countries. As a result, terms such as “financial burden,” “financial hardship,” and “financial toxicity” have risen, especially in the US, to describe the untenable phenomenon patients, particularly those treated for cancer, face: treatment can result in long-term financial hardship that may be so severe as to result in medical bankruptcy or inability to complete recommended treatment protocols. Moreover, the cost of targeted oral medications for cancer treatment continues to rise. One study using Surveillance, Epidemiology, and End Results (SEER)-Medicare data reported that oral prescription drugs for leukemia increased by 27% between 2007 and 2013, reaching $2.35 billion. Another study analyzing the SEER-Medicare 5% Cancer File showed that mean 30-day total spending on targeted oral anticancer drugs more than doubled in 5 years, from $4011 in 2011 to $8857 in 2016.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2226
Issue No: Vol. 9, No. 9 (2023)
-
- Checkpoint Inhibitors Plus Stereotactic Body Radiotherapy in Patients With
Advanced Solid Tumors-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1205 - 1213
Abstract: This randomized clinical trial assesses the addition of radiotherapy to immune checkpoint inhibitors compared with immune checkpoint inhibitor monotherapy in patients with advanced solid tumors.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2132
Issue No: Vol. 9, No. 9 (2023)
-
- Wildfire Exposure During Lung Cancer Surgery Recovery
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1214 - 1220
Abstract: This cohort study assesses the association between wildfire exposure and overall survival among US patients recovering from lung cancer surgery.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2144
Issue No: Vol. 9, No. 9 (2023)
-
- COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in
Patients With Cancer-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1221 - 1229
Abstract: This cohort study examines the incidence rate of severe COVID-19 disease outcomes associated with the number of vaccine doses received and the waning of protection over time.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2271
Issue No: Vol. 9, No. 9 (2023)
-
- Treatment With Niraparib Maintenance Therapy in Patients With Newly
Diagnosed Advanced Ovarian Cancer-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1230 - 1237
Abstract: This randomized clinical trial examines the efficacy and safety of treatment with niraparib with an individualized starting dose in Chinese patients with newly diagnosed advanced ovarian cancer.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2283
Issue No: Vol. 9, No. 9 (2023)
-
- Cost of Drug Wastage From Dose Modification and Discontinuation of Oral
Anticancer Drugs-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1238 - 1244
Abstract: This economic evaluation estimates the cost of pill wastage due to either dose modification or discontinuation for new US Food and Drug Administration–approved or commonly prescribed oral chemotherapy drugs.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2306
Issue No: Vol. 9, No. 9 (2023)
-
- Integrated Clinical-Molecular Classification of Colorectal Liver
Metastases-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1245 - 1254
Abstract: This prognostic study presents clinical validation of a novel 31-gene classifier that accurately predicts colorectal liver metastasis molecular subtypes as a secondary analysis of the large multicenter randomized clinical trial.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2535
Issue No: Vol. 9, No. 9 (2023)
-
- Vigorous Intermittent Lifestyle Physical Activity and Cancer Among
Nonexercising Adults-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1255 - 1259
Abstract: This prospective cohort study evaluates the dose-response association of device-measured daily vigorous intermittent physical activity with incident cancer risk among a large cohort of inactive adults.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.1830
Issue No: Vol. 9, No. 9 (2023)
-
- Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1260 - 1266
Abstract: This cohort study examines the long-term efficacy and safety of tepotinib in patients with MET exon 14–skipping non–small cell lung cancer as a secondary analysis of patients in the VISION nonrandomized clinical trial.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.1962
Issue No: Vol. 9, No. 9 (2023)
-
- Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Paclitaxel for
Metastatic ER+/ ERBB2 − Breast Cancer-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1267 - 1272
Abstract: This randomized clinical trial compares the efficacy, in terms of clinical outcomes and disease control rate, of an all-oral metronomic vinorelbine plus cyclophosphamide plus capecitabine regimen with weekly paclitaxel among patients with estrogen receptor–positive, ERBB2-negative metastatic breast cancer.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2150
Issue No: Vol. 9, No. 9 (2023)
-
- CDK4/6 Inhibitors for Treatment of Hormone Receptor–Positive,
ERBB2-Negative Breast Cancer-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1273 - 1282
Abstract: This review discusses the evidence on cyclin-dependent kinase 4/6 inhibitors for the treatment of hormone receptor–positive, ERBB2-negative breast cancer.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2000
Issue No: Vol. 9, No. 9 (2023)
-
- Management of Down Syndrome–Associated Leukemias
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1283 - 1290
Abstract: This review analyzes the clinical presentation, current treatment, and recent biological insights for children, adolescents, and young adults with Down syndrome–associated acute leukemia.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2163
Issue No: Vol. 9, No. 9 (2023)
-
- Scattered Painful Papulonodules in an Older Woman
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1291 - 1292
Abstract: A 56-year-old woman was admitted for myeloablative conditioning in preparation for allogeneic hematopoietic cell transplant. Her course was complicated by severe mucositis, acute kidney injury, and neutropenic fever. During her admission, she also developed painful necrotic skin lesions, a nonproductive cough, and altered mental status. What is your diagnosis'
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2170
Issue No: Vol. 9, No. 9 (2023)
-
- Mortality in the US Populations With MGUS
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1293 - 1295
Abstract: This cohort study analyzes a nationally representative sample with a screening test for monoclonal gammopathy of undetermined significance (MGUS) to evaluate overall survival of populations with MGUS compared with those without MGUS among the general population in the US.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2278
Issue No: Vol. 9, No. 9 (2023)
-
- Corticosteroids and Survival Outcomes in Patients With Metastatic Renal
Cell Carcinoma-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1295 - 1298
Abstract: This nonrandomized controlled trial ancillary study evaluates the survival outcomes associated with corticosteroid use during nivolumab treatment for patients with metastatic renal cell carcinoma.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2296
Issue No: Vol. 9, No. 9 (2023)
-
- Classification of Breast Cancer According to ERBB2 Immunohistochemistry
Scores-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1298 - 1299
Abstract: To the Editor While we were impressed by the size (n = 1 136 016) of the recent study by Peiffer et al published in JAMA Oncology that analyzed clinical data from the National Cancer Database (NCDB), this large-scale retrospective cohort of patients with ERBB2-negative and ERBB2-low disease used a legacy ERBB2 (formerly HER2 or HER2/neu) immunohistochemistry (IHC) assay read by pathologists. Although the authors report minimal prognostic differences in terms of overall survival between ERBB2-low (IHC 1+ or 2+/in situ hybridization negative) and ERBB2-negative (IHC 0) groupings, they acknowledge that these legacy assays were not designed to distinguish ERBB2-low from ERBB2-negative tumors. We think this limitation led them to a false conclusion that “these findings do not support the classification of ERBB2-low breast cancer as a unique disease entity.”
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2635
Issue No: Vol. 9, No. 9 (2023)
-
- Classification of Breast Cancer According to ERBB2 Immunohistochemistry
Scores—Reply-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1299 - 1300
Abstract: In Reply We appreciate the insightful comments by Robbins and colleagues regarding the appropriateness of immunohistochemistry (IHC) to define ERBB2-low and ERBB2-negative breast cancer in our study. ERBB2-low has been defined as IHC 1+ or 2+ with negative in situ hybridization testing in the US Food and Drug Administration labeling for trastuzumab deruxtecan, and this categorization is widely recognized in national guidelines. Studies critiquing the consistency of IHC grading were conducted prior to recognition of the importance of distinguishing IHC 0 and 1+ disease and may underestimate the true rates of reproducibility achieved by pathologists today. Given the widespread use of IHC to identify patients with low levels of ERBB2 expression, it is premature to characterize IHC as a “legacy” assay. This definition of ERBB2-low has been investigated as a prognostic marker in numerous studies, and we used this same definition in our work to further clarify the clinical implications of ERBB2-low status. It is possible that categorization using other assays can identify distinct prognostic subgroups, but no consistent alternative definition of ERBB2-low has yet emerged.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2638
Issue No: Vol. 9, No. 9 (2023)
-
- Errors in the Conflicts of Interest Section, Figure 2, and Affiliations
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1300 - 1300
Abstract: In the article titled “Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial” published on June 4, 2023, in JAMA Oncology, there were errors in the conflicts of interest section that did not correctly reflect the trademarked referenced entities. In addition, some of the author affiliations were updated, and there was a missing mark in the L-positive section of Figure 2, panel B. This article was corrected online.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2810
Issue No: Vol. 9, No. 9 (2023)
-
- Sunsets
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1302 - 1303
Abstract: My Aunt Susie had a shock of sunset orange hair that Bloomed through the visors she always wore, the visors perched Only inches above the glioblastoma that crashed into her life As a seizure while she strolled around the lagoon behind her house, Savoring the birdsong and San Diego breeze.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.2179
Issue No: Vol. 9, No. 9 (2023)
-
- FDG PET Scans in Cancer Care
-
Free pre-print version: Loading...Rate this result: What is this?Please help us test our new pre-print finding feature by giving the pre-print link a rating.
A 5 star rating indicates the linked pre-print has the exact same content as the published article.
Pages: 1304 - 1304
Abstract: This JAMA Oncology Patient Page explains FDG PET scans and how they are used in cancer care.
PubDate: Fri, 01 Sep 2023 00:00:00 GMT
DOI: 10.1001/jamaoncol.2023.0265
Issue No: Vol. 9, No. 9 (2023)
-
